2018 Rheumatoid Arthritis Chronic Disorder Market Growth Analysis

67 %
33 %
Information about 2018 Rheumatoid Arthritis Chronic Disorder Market Growth Analysis
Health & Medicine

Published on January 30, 2014

Author: mariarobert1213

Source: slideshare.net

Description

Complete report is spread across 85 pages is available @ http://www.reportsnreports.com/reports/274315-advanced-in-the-rheumatoid-arthritis-market.html.

Advanced in the Rheumatoid Arthritis Market report forecast the immunology market will be worth over US$38.5bn as leading players focus on growing their RA franchises in the emerging markets, launch innovative targeted synthetic DMARDs and biologic DMARDs to address unmet clinical needs and biosimilars emerge in the European market to carve out US$3bn share of revenues.

Advanced in the Rheumatoid Arthritis Market Published: January 2014 Single User PDF: US$ 1545 Corporate User PDF: US$ 9270 Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. © ReportsnReports.com / Contact sales@reportsandreports.com 1

Advanced in the Rheumatoid Arthritis Market Rheumatoid arthritis (RA) is a chronic disorder for which there is currently no cure. It affects around 23.5 million adults in the world (WHO, 2013) and approximately 294,000 children under the age of 18 are affected by pediatric arthritis and other rheumatologic conditions (PhRMA, 2013). In 2012, immunology drugs generated global sales of around US$36.6bn of which two thirds were associated with the management rheumatology related conditions (US$24.5bn), the remainder of sales were split evenly between the treatment of dermatological and gastroenterology related conditions. Revenues growth has been driven by improvements in diagnosis and early, more aggressive treatment of RA, the approval of new disease modifying anti rheumatic drugs (DMARDs), new formulations/devices and line extensions. By 2018, Analyst forecast the immunology market will be worth over US$38.5bn as leading players focus on growing their RA franchises in the emerging markets, launch innovative targeted synthetic DMARDs and biologic DMARDs to address unmet clinical needs and biosimilars emerge in the European market to carve out US$3bn share of revenues. The market is on the cusp of change as the first orally active biologic Xeljanz (tofacitimib) from Pfizer/Takeda entered the US market at the end of 2012; several new synthetic and biological DMARDs are in late stage clinical development and Europe approved the first biosimilar generic infliximab (Remicade) from Celltrion/Egis and Hospira in September 2013. Generic entanercept (Enbrel) is not far behind from Baxter/Cogerus and several manufacturers have begun to make copycat versions of Humira which goes off patent in the US in 2016. Inquiry Before Buying on this Report @ http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=274315. Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. © ReportsnReports.com / Contact sales@reportsandreports.com 2

Advanced in the Rheumatoid Arthritis Market This report examines in more detail the recent developments that have occurred in the RA market, including the expansion of approved products for new indications, formulations and new market launches and analyses the progression of pipeline products. It assesses how the new American College of Rheumatology (ACR) and European League against Rheumatism (EULAR) guidelines will impact product uptake and discusses the potential impact of biosimilars on the global RA market. Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=274315. List of Tables Table 1: Leading oral synthetic DMARDs11 Table 3: Leading bDMARDs SC formulations22 Table 4: Leading bDMARDs IV formulations23 Table 5: Line extensions of leading DMARDs24 Table 6: Enbrel regional sales 201233 Table 7: Etanercept biosimilars under development34 Table 9: Adalimumab biosimilars under development35 Table 10: Remicade regional sales 201236 And More. Explore more reports on Arthritis Market. Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. © ReportsnReports.com / Contact sales@reportsandreports.com 3

Add a comment

Comments

plastic package bags | 26/02/15
Buy Plastic Package plastic package bags http://globusua.org

Related presentations

Related pages

Rheumatoid Arthritis (RA) Industry Trends and 2018 Market ...

Rheumatoid Arthritis (RA) Industry Trends and 2018 Market Opportunities Analyzed in New Research Report at MarketReportsOnline.com
Read more

Rheumatoid Arthritis Market: Global Industry Analysis ...

Global Rheumatoid Arthritis Market: ... is a chronic inflammatory disorder that ... Rheumatoid Arthritis Market: Global Industry Analysis ...
Read more

Global Rheumatoid Arthritis Market: Trends and ...

Global Rheumatoid Arthritis Market: Overview Rheumatoid arthritis, or RA, is a form of chronic inflammatory disorder that typically affects the
Read more

Global Rheumatoid Arthritis Disease Market 2018 Forecast ...

Global Rheumatoid Arthritis Disease Market 2018 ... com with Rheumatoid Arthritis Market in ... arthritis (RA) is a chronic disorder for ...
Read more

Global Rheumatoid Arthritis Drugs Market 2014-2018

About Rheumatoid Arthritis RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, ...
Read more

Pain Management Therapeutics Market - Global Industry ...

Pain Management Therapeutics Market ... Analysis, Size, Share, Growth, ... of life of the patients suffering from acute or chronic pain disorders.
Read more